Document is current

Article History

Received: 16 July 2025

Accepted: 2 September 2025

First Online: 8 October 2025

Declarations

:

: Minghui Duan: no competing interests to declare.Prithviraj Bose: Grants (Incyte, CTI (now Sobi), MorphoSys (now Novartis), Kartos, Telios, Ionis, Disc, Blueprint, Cogent, Geron, Janssen, Sumitomo, BMS, Karyopharm, Ajax); consulting fees (Incyte, BMS, CTI (now Sobi), GSK, AbbVie, MorphoSys (now Novartis), Karyopharm, PharmaEssentia, Blueprint, Cogent, Novartis, Jubilant, Morphic, Ono, Sumitomo, Keros (now Takeda), Takeda, Raythera, Ionis, Disc, Geron); honoraria for lectures/advisory boards (Incyte, Blueprint, GSK, CTI, AbbVie, Sumitomo, PharmaEssentia).Zhijian Xiao: no competing interests to declare.Anthony M Hunter: has received honoraria/consulting fees from GSK, Cogent Biosciences, PharmaEssentia, Blueprint Medicines, CTI Biopharma (now Sobi) and Incyte; declares research funding from Incyte, Cogent Biosciences, Ascentage Pharma, Blueprint Medicines, Syntrix Biosystems, Novartis, Shenzen TargetRx, and PharmaEssentia.Albert Qin: serving as the chief medical officer of PharmaEssentia Corporation.Long Chang: no competing interests to declare.Wenxin Li: no competing interests to declare.Daoxiang Wu: employed by PharmaEssentia Biotech Ltd (Beijing).Raajit K. Rampal: Grants (Incyte, Ryvu, MorphoSys, Zentalis); consulting fees (MorphoSys, CTI, GSK, Stemline, Blueprint, SDP, Servier, Zentalis, BMS, Galectco, AbbVie, PharmaEssentia, Cogent, Kartos); honoraria for lectures/advisory boards (Protagonist, Karyopharm, GSK); monitoring or advisory board (Kartos).